Conference Reports for NaTaP

EASL - The International Liver Congress 2015 50th annual Meeting of the European association for the Study of the Liver Vienna, austria  april 22-26 Back

GS-9857 Pangenotypic Protease Inhibitor + SOF/GS5816 for 6/8 Weeks       EASL: SAFETY AND EFFICACY OF SHORT-DURATION TREATMENT WITH GS-9857 COMBINED WITH SOFOSBUVIR/GS-5816 IN TREATMENT-NAIVE AND DAA-EXPERIENCED GENOTYPE 1 PATIENTS WITH AND WITHOUT CIRRHOSIS - (04/23/15)   EASL: Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C - (04/24/15)   EASL: Evaluation of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 in Healthy Volunteers - (04/29/15)   EASL: Preclinical Profile of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 - (04/29/15)   EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver Vienna, Austria April 22-26